 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...102103104105106107108109110111112...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era. (Pubmed Central) - May 15, 2019
It occurs mainly among patients with hypoalbuminemia who receive treatment with cetuximab or chemotherapy. The development of BSI in patients with HNC impairs their outcome, especially in the presence of hypoalbuminemia and comorbidities.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Observational data, Journal: Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. (Pubmed Central) - May 15, 2019
The development of BSI in patients with HNC impairs their outcome, especially in the presence of hypoalbuminemia and comorbidities. The expected efficacy and safety of first-line cetuximab-containing chemotherapy were demonstrated in patients with metastatic colorectal cancer under clinical practice in Japan.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. (Pubmed Central) - May 14, 2019
PI3K activation plays a central role in the acquired resistance to the combination of anti-EGFR and MEK-inhibitor in KRAS mutated colorectal cancer cell lines. PI3K activation is cooperatively achieved through the activation of multiple RTKs such as HER2, HER3 and IGF1R.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Review, Journal: The optimal neoadjuvant treatment of locally advanced esophageal cancer. (Pubmed Central) - May 14, 2019
Cetuximab has also been tested as addition to neoadjuvant- and definitive treatment in patients with locally advanced esophageal cancer, showing mixed results. This review aims at providing an overview of the currently available neoadjuvant treatments in esophageal cancer.
- | Trial completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - May 14, 2019
P1, N=354, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
This review aims at providing an overview of the currently available neoadjuvant treatments in esophageal cancer. Trial completion date: Oct 2019 --> Oct 2020
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (clinicaltrials.gov) - May 14, 2019
P2, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2019 --> Oct 2020 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Enrollment change, Trial withdrawal: QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. (clinicaltrials.gov) - May 13, 2019
P1b/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 N=427 --> 0 | Not yet recruiting --> Withdrawn
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: galactose-α-1,3-galactose (α-gal) (Pubmed Central) - May 13, 2019
N=427 --> 0 | Not yet recruiting --> Withdrawn No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients (clinicaltrials.gov) - May 13, 2019
P=N/A, N=43, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
No abstract available Trial completion date: Jan 2021 --> Sep 2019 | Trial primary completion date: Jun 2020 --> Sep 2019
- || Enrollment closed, Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - May 13, 2019
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Jan 2021 --> Sep 2019 | Trial primary completion date: Jun 2020 --> Sep 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019
- ||| Enrollment closed, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - May 13, 2019
P1/2, N=382, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019 Recruiting --> Active, not recruiting
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cetuximab is an EGF receptor antibody that causes renal magnesium wasting by competing with EGF for its receptor #NKFClinicals 🇺🇸 #Nephpearls #Onconephrology 🦀 👉🏼 https://t.co/LcZLLgWKiZ (Twitter) - May 12, 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cetuximab? (Twitter) - May 12, 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Deep Phospho- and Phosphotyrosine Proteomics Identified Active Kinases and Phosphorylation Networks in Colorectal Cancer Cell Lines Resistant to Cetuximab. (Pubmed Central) - May 11, 2019
Treatment with an SRC inhibitor significantly inhibited proliferation of HCT116 cells. In summary, our results based on deep phosphoproteomic data led us to propose novel therapeutic targets against cetuximab resistance and showed the potential for anti-cancer therapy.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. (Pubmed Central) - May 11, 2019
Study 2B: median PFS was 7.7 (95%CI 4.1-10.1) and 4.9 (95%CI 3.2-7.0) months for CT + Bev and CT + Cet + Bev arms, respectively, with a HR = 1.31 (95%CI 0.76-2.26, p = 0.330). Notwithstanding limitations due to the small sample size, among patients with WT KRAS the addition of Cet to second-line CT increased PFS, whereas the addition of Cet to CT + Bev was associated with worse PFS.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO Biomarker: Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. (Pubmed Central) - May 10, 2019
Since the advent of cetuximab, clinical cancer treatment has evolved from the standard, relatively nonspecific chemo- and radiotherapy with significant cytotoxic side effects towards immunotherapeutic approaches with selective, target-mechanism-based effects...Overall, these results show that our approach can identify and prioritize TNBC targets suitable for targeted therapy. Therefore, our method has the potential to lead to new and more effective immunotherapeutic cancer treatment.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer (clinicaltrials.gov) - May 9, 2019
P2, N=59, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Thought provoking @JCO_ASCO paper by Federico Innocenti Chemo+Bev could be frontline Rx in MSI-h mCRC(not affording IO) considering the mOS of 30m compared to only 11.9 m with cetuximab @ASCOPost @rcarvalhoonco @DrR_DUNNE @ShaalanBeg @CathyEngMD @OncoAlert @pashtoonkasi (Twitter) - May 9, 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: TIME-PRODIGE 28 UNICANCER: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - May 9, 2019
P2, N=134, Recruiting, Sponsor: UNICANCER
Therefore, our method has the potential to lead to new and more effective immunotherapeutic cancer treatment. Trial completion date: Jun 2020 --> Mar 2022 | Trial primary completion date: Feb 2018 --> Oct 2019
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) (clinicaltrials.gov) - May 8, 2019
P2, N=54, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. (Pubmed Central) - May 8, 2019
The small sample size of the present study, especially for logistic regression analysis, is a limitation. In conclusion, instrumental evaluation declared rapid inflammatory changes of the skin by EGFRI and elucidated oily skin as a risk for severe AfE.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR inhibitor C225 Increases the Radio-Sensitivity of Human Breast Cancer Cells (Pubmed Central) - May 8, 2019
In conclusion, instrumental evaluation declared rapid inflammatory changes of the skin by EGFRI and elucidated oily skin as a risk for severe AfE. could increase the radio-sensitivity of cells, which may be due to the anti-proliferative synergistic effect between C225and radiation as well as the down-regulation of the PI3K/Akt signaling pathway.
- ||| anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
Enrollment open, Enrollment change, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - May 7, 2019
P1, N=230, Recruiting, Sponsor: Celgene
could increase the radio-sensitivity of cells, which may be due to the anti-proliferative synergistic effect between C225and radiation as well as the down-regulation of the PI3K/Akt signaling pathway. Not yet recruiting --> Recruiting | N=140 --> 230
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: COMMENCE: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - May 7, 2019
P1/2, N=52, Active, not recruiting, Sponsor: Radboud University
Not yet recruiting --> Recruiting | N=140 --> 230 Recruiting --> Active, not recruiting | Trial completion date: Feb 2018 --> Dec 2020 | Trial primary completion date: Nov 2017 --> Dec 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Retrospective data, Review, Journal, HEOR, Combination therapy: Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - May 7, 2019
Although this advantage may be considered clinically modest, bevacizumab represents a hope for increased survival and a chance of metastasectomy for patients with mCRC. However, there are serious adverse events associated with its use, especially severe hypertension and gastrointestinal perforation, that need to be considered.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal, Real-World Evidence: Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. (Pubmed Central) - May 7, 2019
However, there are serious adverse events associated with its use, especially severe hypertension and gastrointestinal perforation, that need to be considered. Inflammatory factors enrolled in the proposed nomograms showed accurately individualized prognostic prediction, and prognostic factors for RSCC and LSCRC were different.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies. (Pubmed Central) - May 6, 2019
Finally, in a cohort of xenopatients, stratified for response to cetuximab, we observed an inverse association between the expression level of LRIG1 and CRC progression upon CTX treatment. Our model implies that combining GR modulation to EGFR inhibition may yield an effective treatment strategy in halting cancer progression.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 6, 2019
P1, N=16, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Our model implies that combining GR modulation to EGFR inhibition may yield an effective treatment strategy in halting cancer progression. Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2019 --> Apr 2020
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Clinical: 1/3 First in human #clinicaltrial of #regorafenib + cetuximab in #colorectal #cancer & others. https://t.co/o5UqO9hi9T @CathyEngMD @skopetz @DavidHongMD @JCI_insight #crcsm (Twitter) - May 4, 2019
- | Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - May 3, 2019
P1, N=16, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2019 --> Apr 2020 Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders. (Pubmed Central) - May 2, 2019
Moreover, a two-step procedure involving vNAR-functionalized beads was employed for the enrichment of potentially bispecific cetuximab × matuzumab antibody constructs. In conclusion, semi-synthetic and CDR3-randomized vNAR libraries in combination with yeast display enable the fast and facile identification of anti-idiotypic vNAR domains targeting monoclonal antibodies primarily in an anti-idiotypic manner.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. (Pubmed Central) - May 2, 2019
• In colorectal cancer, increased attenuation of liver metastases in baseline computed tomography is a prognostic factor for prolonged OS (p < 0.001). • A threshold of ≥61.62 HU was determined as optimal cut-off to identify patients with prolonged OS (p < 0.001), early tumour shrinkage (p = 0.002) and increased depth of response (p = 0.012).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis. (Pubmed Central) - May 2, 2019
Patients with NPC receiving additional cetuximab treatment can benefit more from this systemic comprehensive therapy, while the efficiency of conventional treatment for NPC is limited. ST associated with cetuximab may be used as a potential on-treatment marker to guide treatment with cetuximab against NPC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 2, 2019
P2, N=70, Recruiting, Sponsor: Washington University School of Medicine
ST associated with cetuximab may be used as a potential on-treatment marker to guide treatment with cetuximab against NPC. Trial completion date: May 2021 --> Jun 2020 | Trial primary completion date: May 2019 --> May 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab. (Pubmed Central) - Apr 30, 2019
Trial completion date: May 2021 --> Jun 2020 | Trial primary completion date: May 2019 --> May 2020 No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. (Pubmed Central) - Apr 30, 2019
As most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Antibody-functionalized gold nanoparticles as tumor targeting radiosensitizers for proton therapy. (Pubmed Central) - Apr 30, 2019
Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Combination therapy: Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report. (Pubmed Central) - Apr 30, 2019
We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL and CTX treatment.
- ||| monalizumab (IPH2201) / AstraZeneca, Innate
Enrollment change, Trial completion date, Trial primary completion date, Metastases: IPH2201-203: Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 30, 2019
P1b/2, N=140, Recruiting, Sponsor: Innate Pharma
Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL and CTX treatment. N=100 --> 140 | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (clinicaltrials.gov) - Apr 30, 2019
P1, N=10, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
N=100 --> 140 | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Oct 2017 --> Jun 2019
- ||| Nanoplatin (demplatin pegraglumer) / NanoCarrier, Orient Europharma
Trial completion, Enrollment change, Combination therapy, Metastases: NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 29, 2019
P1/2, N=1, Completed, Sponsor: NanoCarrier Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Oct 2017 --> Jun 2019 Active, not recruiting --> Completed | N=80 --> 1
- | PHA665752 / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Effects of PHA-665752 and cetuximab combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with KRAS or BRAF mutations. (Pubmed Central) - Apr 28, 2019
Active, not recruiting --> Completed | N=80 --> 1 Combination treatment with PHA-665752 and cetuximab suppressed in vitro and in vivo CRC cell growth more than treatment with either agent alone did.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Combination therapy: Enhanced cell killing and apoptosis of oral squamous cell carcinoma cells with ultrasound in combination with cetuximab coated albumin microbubbles. (Pubmed Central) - Apr 26, 2019
Time-signal intensity curve in a tissue phantom demonstrated clear visualization of CCAM with conventional US imaging device. Our experiment verifies the hypothesis that CCAM was selective to HSC-2 cells and may be applied as a novel therapeutic/diagnostic microbubble for oral squamous cell carcinoma.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database. (Pubmed Central) - Apr 26, 2019
These data suggest that costs of care in patients with recurrent or refractory HNC are related to patient characteristics and treatment patterns. Identification of factors contributing to the costs of care in HNC may provide a useful foundation for developing strategies to control rising costs.
- | Votrient (pazopanib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P1 data, Journal: Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. (Pubmed Central) - Apr 26, 2019
P1
Pazopanib oral suspension at a dose of 800 mg/day was feasible to administer in combination with standard weekly cetuximab for patients with recurrent or metastatic HNSCC. Encouraging preliminary antitumour activity was observed with this combination therapy and warrants further validation in randomised trials.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: CheckMate 141 Trial: all that glitters is not gold. (Pubmed Central) - Apr 26, 2019
Encouraging preliminary antitumour activity was observed with this combination therapy and warrants further validation in randomised trials. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. (Pubmed Central) - Apr 25, 2019
YB-1 was highly phosphorylated in CRC patient tumor tissues and was mainly localized in the nucleus. Together, dual targeting of RSK and Akt may be an alternative molecular targeting approach to cetuximab for treating CRC in which YB-1 is highly phosphorylated.
- |||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical: Fascinating paper. My lab together with Cyril Benes is moving to 3D, better simulates in vivo tumor phenotype, and, relevant for #radonc benchmarking, reproduces radiosensitization by cetuximab and KRASmut radioresistance much better than 2D @MGHCancerCenter (Twitter) - Apr 25, 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. (Pubmed Central) - Apr 24, 2019
Previous bevacizumab use had no effect on the activity of subsequent EGFRIs. The apparent effect of time between biologic agents in right-sided tumors might reflect patient selection.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. (Pubmed Central) - Apr 24, 2019
DNA repair genes may play a significant role in the pharmacogenetics of aCRC. Our data suggest that both common and rare DPYD variants may be associated with toxicity to fluoropyrimidine-based chemotherapy.